Characteristics of the patients grouped according to the extent of BM microvessel area
| Variable3-150 . | Microvessel area . | P . | |
|---|---|---|---|
| < 0.90 mm2 × 10−2 . | ≥ 0.90 mm2 × 10−2 . | ||
| Age, y | 65 (42-74) | 62 (45-81) | .724 |
| Sex, M/F | 21/12 | 8/4 | .851 |
| Rai substages | |||
| 0 | 21 | 6 | .222 |
| I-II | 12 | 6 | .320 |
| PB lymphocytes, × 109/L | 20.7 (5-100) | 22.5 (5-75) | .989 |
| BM histology, nondiffuse/diffuse | 32/1 | 12/0 | .542 |
| LDH, U/L | 431 (129-953) | 486 (36-931) | .615 |
| β2-m, ng/mL | 2.66 (1.6-8.0) | 3.20 (1.8-7.25) | .322 |
| Lymphocyte doubling time, ≥ 12 mo | 72.7% | 83.3% | .464 |
| sVEGF, pg/mL | 218 (9-1120) | 168 (36-2000) | .432 |
| sFGF-2, pg/mL | 35.9 (6-206) | 36.8 (2-142) | .912 |
| Cytogenetics | |||
| Normal karyotype | 10 | 3 | .462 |
| 13q as a sole aberration | 5 | 1 | |
| 12q trisomy | 8 | 0 | |
| 11q or 17p deletion | 2 | 0 | |
| Variable3-150 . | Microvessel area . | P . | |
|---|---|---|---|
| < 0.90 mm2 × 10−2 . | ≥ 0.90 mm2 × 10−2 . | ||
| Age, y | 65 (42-74) | 62 (45-81) | .724 |
| Sex, M/F | 21/12 | 8/4 | .851 |
| Rai substages | |||
| 0 | 21 | 6 | .222 |
| I-II | 12 | 6 | .320 |
| PB lymphocytes, × 109/L | 20.7 (5-100) | 22.5 (5-75) | .989 |
| BM histology, nondiffuse/diffuse | 32/1 | 12/0 | .542 |
| LDH, U/L | 431 (129-953) | 486 (36-931) | .615 |
| β2-m, ng/mL | 2.66 (1.6-8.0) | 3.20 (1.8-7.25) | .322 |
| Lymphocyte doubling time, ≥ 12 mo | 72.7% | 83.3% | .464 |
| sVEGF, pg/mL | 218 (9-1120) | 168 (36-2000) | .432 |
| sFGF-2, pg/mL | 35.9 (6-206) | 36.8 (2-142) | .912 |
| Cytogenetics | |||
| Normal karyotype | 10 | 3 | .462 |
| 13q as a sole aberration | 5 | 1 | |
| 12q trisomy | 8 | 0 | |
| 11q or 17p deletion | 2 | 0 | |
Ranges are presented in parentheses.
Variables were assessed in all 45 patients except those of lymphocyte doubling time and cytogenetics, which were assessed in 38 and 28 patients, respectively.